|
|
 |
 |
 |
 |
 |
 |
 |
September 26, 2005
Domestic Clinical Trial for NFκB Decoy Oligo Launched
− Phase I Clinical Trial in Atopic Dermatitis Commences − |
 |
|
|
AnGes MG has been preparing a phase I clinical trial for NFκB decoy oligo and is now pleased to announce that the trial has been launched as the drug was administered to the trial participants.
AnGes MG has been developing NFκB decoy oligo as a gene-based therapy that treats immune inflammatory diseases including atopic dermatitis and rheumatic arthritis. Although there are as many as 1.4 million patients with atopic dermatitis in Japan, no effective drugs have been developed yet for sufferers of severe facial atopic dermatitis.The development of new treatments for the diseases is anxiously awaited.
AnGes MG has prepared a clinical trial in Japan against this background because NFκB decoy oligo can specifically inhibit transcription factors, leading to the possibility for the development of an innovative and effective therapeutic agent with minimal side effects.
This phase I clinical trial is to be conducted to confirm the safety of intradermal administration of NFκB decoy oligo. In addition to the HGF plasmid project, for which clinical trials are ongoing both in the US and Japan, the development of the NFκB decoy oligo project has also moved to the clinical trial phase. The Company’s development portfolio has thus been further enriched with the initiation of this clinical trial.
AnGes’ NFκB decoy oligo therapy for atopic dermatitis is being jointly developed with Alfresa Pharma Corporation in Japan. |
| Reference |
|
|
|
| Development Status of NFκB Decoy Oligo |
| Field of indications |
Region |
Development Phase |
Licensee |
| Atopic dermatitis |
Japan |
Phase I clinical trial |
Alfresa Pharma Corporation |
| Psoriasis |
|
Preclinical |
Undecided |
| Rheumatoid arthritis |
|
Clinical trial under preparation |
Seikagaku Corporation |
| Osteoarthritis |
|
Preclinical |
| Prevention of vascular restenosis |
|
Clinical trial under preparation |
Goodman Co., Ltd. |
|
| Note: The underlined item is the updated topic. |
|
|
|
